Living Cells Tech Files Patent for Cannabis-Based Dementia Drug - Kalkine Media

July 27, 2023 06:50 AM AEST | By Team Kalkine Media
Follow us on Google News:

Living Cell Technologies (ASX: LCT) has taken a significant step in the field of cannabis-based medicine by filing a provisional patent application for a CBD-based combination drug called AI-116, designed to treat dementia. This move establishes the priority date of the invention and positions the company ahead of potential competitors in the rapidly growing dementia drugs market, which was valued at over US$8.7 billion in 2021 and is projected to reach US$19.7 billion by the end of this year.

Antisense Therapeutics (ASX: ANP) experienced a 5% surge in its stock value following a successful study demonstrating the efficacy of its drug, ATL1102, in combination with dystrophin restoration drugs for Duchenne muscular dystrophy (DMD). The results showed improved muscle strength and indicated ATL1102's potential to enhance therapeutic outcomes in DMD patients.

Radiopharmaceutical company Clarity Pharmaceuticals (ASX: CU6) achieved a significant milestone by completing cohort 3 in the theranostic 64Cu/67Cu SARTATE neuroblastoma trial. This progress has allowed the company to move forward to the final cohort, where the highest dose in the dose escalation phase will be administered to further advance the trial.

Incannex Healthcare (ASX: IHL) made progress in its rheumatoid arthritis drug development by successfully completing a constructive pre-Investigational New Drug Application (pre-IND) meeting with the US FDA. The meeting focused on the formulation of IHL-675A and provided an overview of the proposed clinical development plan. This meeting is a crucial step towards opening an IND for conducting trials in the US and obtaining FDA marketing approval.

These developments showcase the growing interest and potential of ASX cannabis stocks in the field of medical research and treatment. As more companies explore the therapeutic benefits of cannabis-based drugs, investors and researchers alike are closely monitoring the advancements and impact of these innovations in the pharmaceutical industry.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK